Near-term strategies for biotech drug developers facing shifting healthcare dynamics
A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.
Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”
The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025